Endogard Plus

Quick links to important sections

Endogard Plus

Method of action: Anthelmintic

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Endogard Plus

Quick Facts

Property Description
Active ingredient Febantel, Praziquantel, Pyrantel
Form Oral Tablet
Pharmacological class Broad-spectrum Anthelmintic Agent
Common use Control of parasitic worm infestations
Origin Synthetic, Fixed-Dose Combination

What Type of Medicine is Endogard Plus?

Endogard Plus is a veterinary pharmaceutical classified as a broad-spectrum anthelmintic agent designed exclusively for the control and elimination of internal parasitic infestations in canines. The product is defined as a fixed-dose combination (FDC), signifying that it integrates multiple active substances within a single oral tablet to achieve comprehensive efficacy against various helminth species.

It is a synthetic medicine belonging to the antiparasitic agent class. The FDC approach is utilized to ensure effective action across different life cycle stages and species of parasitic worms. Endogard Plus is often produced as a readily accepted, flavored oral tablet, distinguishing its administration profile from unflavored alternatives in veterinary practice.

The Composition: What Active Ingredients Does Endogard Plus Contain?

The formulation relies on the combined action of three distinct active ingredients: Febantel, Praziquantel, and Pyrantel (typically present as the Pyrantel Pamoate salt). These active substances are compounded into a single oral tablet alongside solid pharmaceutical excipients.

This combined therapy is strategically intentional, integrating a pro-benzimidazole derivative (Febantel), an isoquinoline derivative (Praziquantel), and a tetrahydropyrimidine derivative (Pyrantel) to maximize the antiparasitic coverage. These ingredients achieve a potent synergistic effect when used together against common gastrointestinal worms, a mechanism for improving treatment outcomes compared to single-agent options.

What is the General Purpose of This Combination Anthelmintic?

The primary general purpose of this combination anthelmintic is to provide multi-modal action for the efficient control and elimination of common parasitic worms in dogs through one therapeutic entity. This addresses the challenge of managing multiple concurrent parasitic infestations.

The function is achieved through the synergistic effect of the components, which attack the parasite through several physiological pathways, including energy depletion, muscular paralysis, and structural damage to the worm's outer layers. This coordinated multi-modal mechanism ensures a higher likelihood of complete expulsion and elimination of the target helminth species, fulfilling the drug's role as a comprehensive broad-spectrum agent.

What side effects are possible with Endogard Plus?

Officially Documented Adverse Reactions

The safety profile of this triple-combination anthelmintic is defined by documented potential disturbances within a single System-Organ Class: Gastrointestinal Disorders. The primary adverse reactions reported in official regulatory documents are vomiting and diarrhoea or loose stools.

Population Frequency Classification Adverse Reactions
Adult Dogs Very Rare (<1 in 10,000 animals treated) Vomiting, Diarrhoea
Puppies Rare (1 to 10 in 10,000 animals treated) Loose Stools, Diarrhoea, Vomiting

Adverse effects observed in puppies are characterized in regulatory documents as transient.


Safety Constraints and Restrictions

Official safety labeling details specific contraindications and constraints based on population and co-administration with other compounds. The product must not be used in dogs younger than 2 weeks of age and/or weighing less than 2 kg. Use in bitches is contraindicated during the first two-thirds of pregnancy, though use during lactation is permitted, provided the stated dosage is not exceeded.

Furthermore, the regulatory text explicitly restricts the simultaneous use of this medicine with piperazine compounds due to potential antagonism of effects. Concurrent use with other cholinergic compounds is also noted to carry a risk of toxicity, defining a mandatory safety restriction for its administration. Use is also contraindicated in animals with known hypersensitivity to the active substances or excipients.

The official documentation confines the understanding of risk to a narrow physiological system and specific, contraindicative circumstances.

Overdose and Emergency Response

The official regulatory profile for Endogard Plus overdose is established through safety data documented by government authorities. This profile specifies the documented clinical and physiological findings observed during tolerance studies in the target species.

Documented Manifestations and Physiological Effects

Clinical signs observed in overdose studies involving doses up to five times the recommended label dosage include the occurrence of vomition and non-formed stools. At this high exposure level, physiological findings documented in the regulatory text include the transient elevation of liver enzymes (SGPT, SGOT, GGT) and Creatine Phosphokinase (CPK). The product is formally stated to be well tolerated by the target species at this dose.

Emergency Actions and Required Management

Regulatory information confirms that no specific antidote is known for treating an overdose with this combination product. Therefore, the officially required approach to management is symptomatic and supportive treatment, addressing the manifestations as they arise.

The only circumstance requiring mandatory help-seeking action specified in the official labeling relates to accidental human ingestion. In this event, individuals must seek medical advice immediately and are instructed to show the package leaflet to the physician. This protocol defines the required regulatory action for seeking urgent help.

Therapeutic Uses of Endogard Plus

What Endogard Plus Treats: Main Uses and Benefits

Endogard Plus is utilized to support the management of various infectious conditions associated with susceptible organisms. The medication provides a therapeutic option for conditions involving roundworms (such as Toxocara canis and Toxascaris leonina), hookworms (Uncinaria stenocephala and Ancylostoma caninum), and tapeworms (Taenia species and Dipylidium caninum). These indications represent the spectrum of therapeutic use for the product.

The medication is commonly recommended in clinical scenarios where comprehensive parasite management is required to help address an active infestation and support patient comfort during recovery. The principal advantage is the potential to relieve discomfort and other associated symptoms resulting from the underlying parasitic infection.

Quick Fact: Relief for Parasitic Infestation Symptoms

Regulatory References

  1. VMD Public Assessment Report for Endogard Plus

Eligibility and Restrictions for Use

Eligibility for Use

Regulatory documents define the populations permitted, restricted, or prohibited from using Endogard Plus. The medicine is authorized solely for dogs and is generally approved for adult dogs and puppies from a specified minimum age and weight.


Contraindications (Who Must Not Use)

Endogard Plus is strictly contraindicated in several specific populations:

  • Dogs with a known hypersensitivity to Praziquantel, Febantel, Pyrantel, or any of the inactive excipients.
  • Puppies younger than 2 weeks of age and dogs weighing less than 2 kg.
  • Dogs concurrently receiving piperazine compounds or other cholinergic agents, as this combination is prohibited by the regulatory label.

Restricted Use Populations

  • Pregnancy: Use is not recommended in bitches during the first two-thirds of pregnancy. If used in later stages, the stated dosage must not be exceeded.
  • Lactation: The product may be used during lactation (breastfeeding).

Regulatory documentation does not specify contraindications based on hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official regulatory documentation for Endogard Plus, a fixed-dose combination anthelmintic, details specific interaction patterns that can alter the medicine's documented profile for safety and effectiveness. This interaction information is based strictly on data presented in government-approved prescribing information. The primary interactions are categorized based on pharmacodynamic mechanisms.

Interaction Scope and Restrictions

Category of Interacting Substance Official Restriction and Effect
Piperazine Compounds This combination is officially classified as a contraindicated combination. These compounds must not be used simultaneously with Endogard Plus. This required restriction is due to an officially documented antagonistic effect that specifically targets and reduces the anthelmintic action of the Pyrantel component.
Other Cholinergic Compounds Co-administration with these substances is a restricted interaction. Concurrent use is associated with a formally documented risk of toxicity, which is identified as a clinically significant consequence of pharmacodynamic reinforcement.

Interaction Structure Summary

The regulatory profile strictly establishes that the administration of piperazine compounds must be non-concurrent with this medicine, thereby creating a mandatory rule against simultaneous use to prevent therapeutic antagonism. The profile also explicitly identifies other cholinergic compounds as substances that present an elevated safety risk upon co-administration. The interaction constraints defined in the official documentation primarily concern the potential for reduced efficacy or an increased risk of an adverse outcome. This structure defines the essential regulatory boundaries for co-administering this medicine.

Mechanism of Action

Neuromuscular Paralysis and Spastic Control

The mechanism of Endogard Plus relies on the synchronized action of three components. Pyrantel and Praziquantel deliver a multi-modal interaction on the helminth's nervous and muscular systems. Pyrantel acts as an agonist on the parasite's nicotinic acetylcholine receptors (nAChRs), leading to sustained, involuntary muscle contraction and tetanic paralysis. Concurrently, Praziquantel modulates the parasite's calcium ion channels, triggering a massive and uncontrolled Ca^2+ influx that results in immediate, generalized spastic paralysis and significant structural damage to the protective outer layer (tegument). This combined physiological breakdown prevents the worms from resisting expulsion.

Structural Collapse and Metabolic Deprivation

The third component, Febantel (via its active metabolites), involves a gradual metabolic and structural interference pathway. It inhibits the polymerization of the parasite's beta-tubulin protein, thereby destroying the microtubules necessary for maintaining cell structure and transporting nutrients. This disruption blocks the parasite's ability to absorb essential glucose, leading to metabolic energy depletion and eventual cellular death. This slower, fundamental compromise functions synergistically with the neuromuscular mechanisms, resulting in the immediate disablement and irreversible compromise of cellular viability.

Dosage and Administration Information

How Endogard Plus is Used: Administration Guidelines

Administration of Endogard Plus follows standardized protocols which define the application of this fixed-dose combination anthelmintic.


Administration Scope

The approved route of administration for Endogard Plus is oral. The dosing schedule is based on providing a minimum effective dose of each active ingredient—Praziquantel, Febantel, and Pyrantel Pamoate—relative to the subject's body weight. This is achieved through a fixed weight ratio, typically one tablet per 10 kg of body weight, utilizing the available tablet strengths.

Regarding timing in relation to meals, the tablet can be administered with or without food. No complex preparation requirements are specified, as the product is a ready-to-use, flavored oral tablet; however, tablets are designed to be split to accurately meet the required weight-based dose.


Procedural Structure and Use Patterns

The usage protocol establishes that the primary age-group administration rule is dependent on the precise body weight of the canine subject. The medicine is employed in two distinct frequency patterns:

  1. Single Administration: Used as a short-term, one-off treatment course for a diagnosed parasitic infestation.
  2. Intermittent Schedule: Utilized in a long-term control program, with the dose typically repeated at regular intervals, such as every three months.

This structure defines the appropriate context for its use, from acute clearance to ongoing control management.

Recent Clinical Evidence

Endogard Plus: Recent Clinical Evidence

Clinical Efficacy and Target Parasites

Endogard Plus is a veterinary product containing a fixed combination of three active substances: praziquantel, pyrantel embonate, and febantel. The combination is indicated for the treatment of mixed infestations of roundworms and tapeworms in dogs.

Research and regulatory reviews confirm the product's spectrum of activity against several key parasites. Studies report efficacy against major nematodes, specifically Ascarids (Toxocara canis, Toxascaris leonina), and Hookworms (Uncinaria stenocephala, Ancylostoma caninum). The compound also includes activity against Cestodes (Tapeworms), including Taenia species and Dipylidium caninum.

Mechanism of Action Overview

Each component in the combination works through distinct biological pathways. Praziquantel, an anthelmintic widely used in veterinary medicine, has been observed in studies to cause rapid damage to the parasite's outer layer, leading to contraction and paralysis. Pyrantel acts as a nerve-muscle stimulant, causing spastic paralysis in the parasites, facilitating their expulsion from the gastrointestinal system.

Febantel, an inactive compound, is metabolized in the mammalian system to active anthelmintics (fenbendazole and oxfendazole). These metabolites work by disrupting essential processes within the parasite cells, ultimately leading to parasite death within two to three days. The combined use of pyrantel and febantel is reported to act synergistically against the targeted nematodes.

Safety Profile and Interactions

Safety studies conducted in the target species report a wide safety margin, with dosages up to five times the recommended rate giving rise to occasional, transient vomiting in some cases. Rare instances of transient loose feces or diarrhea may occur, particularly in puppies.

Regarding interactions, regulatory information advises against simultaneous use with piperazine compounds, as this combination may interfere with the anthelmintic effects of pyrantel. The use of the product in pregnant bitches requires veterinary consultation, and it is not recommended during the first two-thirds of pregnancy.

Frequently Asked Questions (FAQ)

Common questions about Endogard Plus (FAQ)


Q: How quickly does Endogard Plus start working?

Official regulatory information describes the mechanism of action as involving rapid parasite paralysis for two components (Praziquantel and Pyrantel). The third component, Febantel, works more gradually by disrupting the parasite's energy supply, which is indicated to lead to death within two to three days.


Q: How long does the effect of Endogard Plus last?

The intended duration of use varies based on the purpose described in regulatory documents. The medicine can be used as a single administration for short-term treatment. For long-term control of parasitic worms, regulatory documents describe a routine intermittent schedule, such as repetition at regular intervals.


Q: Are there any foods or drinks to avoid while taking Endogard Plus?

The official product information states that the medicine can be administered with or without food. Regulatory texts do not specify any restrictions on general food or drink intake. The only usage limitations concern avoiding certain classes of other medicines due to potential antagonistic effects.


Q: Is Endogard Plus safe to use for older adults?

Endogard Plus is approved for use in adult dogs who meet the minimum weight and age requirements. Official documents do not include specific precautions, restrictions, or special dosage instructions related to the geriatric (older) dog population.


Q: Are there specific medical conditions that mean I should not use Endogard Plus?

Official documents indicate that the medicine is contraindicated (should be avoided) in animals with a known hypersensitivity (allergy) to any of the active ingredients or excipients. It is also restricted for use in very young, low-weight puppies and pregnant bitches during the early stages of gestation.


Q: Does Endogard Plus affect my ability to drive or operate machinery?

Endogard Plus is a veterinary medicine authorized exclusively for the treatment of dogs. Official regulatory documentation, therefore, does not include information or warnings related to human occupational safety, such as the ability to drive or operate machinery.


Q: Does Endogard Plus need to be taken at a specific time of day?

Regulatory documents do not mandate a specific time of day, such as morning or evening, for administration. The medicine is also stated to be effective whether administered with or without food.


Q: What is the shelf life of Endogard Plus once the package is opened?

The three-year shelf life applies only when the product is stored in its original, sealed blister packaging. Regulatory texts specify that any split tablet parts (halves or quarters) are required to be discarded immediately after use.


Q: Does Endogard Plus come with a patient information leaflet?

Yes. As a regulated veterinary medicinal product, Endogard Plus is supplied with official Product Information (often called a Package Leaflet). This document details the approved use, contraindications, and warnings for the animal owner.


Q: Why is Endogard Plus available by prescription only?

The legal status of prescription-only medicine (POM) is assigned by regulatory bodies. This classification is typically based on factors such as the need for a veterinary diagnosis, the potential risk to the animal if used incorrectly, or the complexity of ensuring accurate, weight-based administration.


Q: Can Endogard Plus be split or crushed?

The tablets are specifically designed to be easily split into halves or quarters to accurately achieve the weight-based dose required by the regulatory guidelines. However, official product information does not include any instructions or commentary regarding the crushing of the tablet.


Q: What are the signs that Endogard Plus is working for me?

Endogard Plus is indicated for the control and elimination of roundworms and tapeworms. Effectiveness relates to the reduction of these parasites. Success is typically confirmed through specific laboratory procedures, such as a fecal parasite count reduction test.


Q: Can children or adolescents use Endogard Plus?

No. Endogard Plus is authorized exclusively as a veterinary medicine for the treatment of dogs. It is not approved, licensed, or intended for use in humans, including children or adolescents.


Q: How is the effectiveness of Endogard Plus measured in clinical trials?

Clinical effectiveness is measured by demonstrating the successful elimination and clearance of the specific target parasites (Ascarids, Hookworms, and Tapeworms) in the treated population. This is usually quantified by tests that measure the reduction in parasite eggs or counts after administration.


Q: What should I do if I accidentally take too much Endogard Plus?

The official regulatory documentation describes the procedure for accidental human ingestion, noting that medical advice should be sought immediately and the product package leaflet presented to the healthcare provider.


Q: Why does Endogard Plus have a long list of potential side effects?

The official product information actually reports a very short range of known adverse reactions, specifically vomiting, diarrhea, and loose stools. These effects are documented as occurring rarely or very rarely. The medicine does not have an officially documented 'long list' of potential side effects.

How should Endogard Plus be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents state that Endogard Plus does not require any special storage conditions for the packaged product, indicating stability under typical ambient conditions. The tablets maintain a shelf-life of 3 years when stored in the original Alu-Alu blister packaging, and they must not be used past the expiry date.

Handling and Protection

The product must be stored out of the sight and reach of children, as is mandatory for pharmaceuticals. Any part-used tablet halves or quarters should be discarded immediately to maintain stability.

Disposal of Unused Medicine

Unused or expired Endogard Plus should not be disposed of via wastewater to prevent environmental contamination. Disposal must be completed through official take-back schemes or applicable national collection systems in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Endogard Plus found in:

A-Z Index: